Navigation Links
Curemark CEO To Deliver Keynote Address at the BioScience Vision Summit

RYE, N.Y., Sept. 16, 2013 /PRNewswire/ -- Curemark LLC announced that CEO Dr. Joan Fallon will deliver the keynote at BioForward's BioScience Vision Summit in Madison, WI on September 18.  Life science entrepreneurs from across the country will attend the event, which focuses on biotechnology partnerships and innovation.

Dr. Fallon's address, "Growth by Association: Winning through Public and Private Partnerships," will highlight the clear benefits of the collaboration of government and business with life sciences stakeholders. Dr. Fallon's Wisconsin speech comes on the heels of her speech to the White House Office of Technology and Science, attended by senior Obama Administration officials.  

Dr. Fallon stated that, "I'm delighted and honored to be asked to deliver the keynote address at such an important conference and looking forward to meeting thought leaders from across the life sciences sector."

"Wisconsin is a center of innovation for the biosciences, which is why this conference is extremely important. Patients want help, particularly for the large number of still-unmet medical needs.  We need novel solutions and new thinking to move biotechnology forward," Dr. Fallon continued.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit

Safe-Harbor Statements

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
2. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
3. Cardiovascular Drug Delivery - Technologies, Markets and Companies - Updated 2012 Report
4. PI USA Offers High-End Compact Rotation Stage; Delivers High Performance and Precision via Air Bearings and Torque Motor
5. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
6. Biotech & BioPharma Professionals: CA Board of Pharmacy Executive, Virginia Herold, to Deliver Keynote at BSMA Annual Biotechnology Conference Oct 8-9
7. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
8. PolyScience Performance Programmable Circulating Baths Deliver Ultra-Precise, Highly Customizable Performance
9. Bend Research Presents Drug Delivery Advancements at Controlled Release Society Annual Meeting
10. Vaginal Ring Provides “Radically New” Drug Delivery Platform for Health Issues, Including Infertility
11. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
Post Your Comments:
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 30, 2015  HUYA Bioscience International, the leader in ... pharmaceutical innovations, today announced it has signed a Memorandum ... to foster collaboration between KDDF and HUYA with the ... healthcare products for the global market. ... of new innovative preclinical and clinical stage compounds. The ...
(Date:11/30/2015)... 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a ... conditions, will present at two upcoming investor conferences. Aytu ... real-time virtual conference, to be held December 3, 2015, ... be held December 2 nd & 3 rd ... and streamed live via webcast. Josh Disbrow ...
(Date:11/30/2015)... 30, 2015  AbbVie, is introducing Good Morning ... a daily routine for managing the life-long condition of ... affect the way the body absorbs it so resources ... daily routine are important. The goal of the new ... manage their hypothyroidism by establishing a daily routine, spirit ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever that ... muscular dystrophy (DMD) has provided a new lead for ... Hospital, the Broad Institute of MIT and Harvard and ... . Cell, pinpoints a ... "escape" the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):